Travere Therapeutics names Bradley Campbell CEO as Eric Dube exits

Travere Therapeutics disclosed on September 21, 2026 that Eric Dube, Ph.D. and the company mutually agreed on a timeline for his departure from the roles of President, Chief Executive Officer, and board member, effective December 1, 2026, which the filing calls the Officer Resignation Date.¹ Bradley L. Campbell will succeed him as President, CEO, and board member effective the same date.¹ Dube has agreed to remain with the company as Executive Advisor through February 15, 2027, and to later serve as a consultant to the CEO.¹

Campbell brings substantial industry experience. He served as President and CEO of Amicus Therapeutics from August 2022 until its acquisition by BioMarin Pharmaceutical in April 2026, having previously been Amicus's President and Chief Operating Officer from January 2015.¹ At Amicus, he led global commercialization of Galafold before becoming CEO.¹

Under the transition agreement, Dube will keep his CEO title and duties until December 1, 2026,¹ then continue as an employee without CEO responsibilities during a transition period.¹ His employment terminates February 16, 2027, unless an earlier date is mutually set.¹ He will keep his base salary and remain eligible for a 2026 bonus, but not a 2027 bonus, and will not receive further equity grants, though existing awards continue vesting through the transition period.

Campbell's employment agreement sets an annual base salary of $1,000,000 and a discretionary bonus target of 85% of base salary.¹ He will also receive up to $10,000 in legal fee reimbursement and a $500,000 expense payment tied to accepting the role.¹ His initial equity awards include a stock option and a time-based RSU award, each valued at approximately $8,250,000.¹ A performance-based RSU award worth about $3,750,000 is planned for early 2027, tied to future corporate, clinical, and regulatory milestones.¹